RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus

Antimicrob Agents Chemother. 2003 Jun;47(6):1979-83. doi: 10.1128/AAC.47.6.1979-1983.2003.

Abstract

Staphylococcus aureus is a prevalent cause of bacterial infections associated with indwelling medical devices. RNA III inhibiting peptide (RIP) is known to inhibit S. aureus pathogenesis by disrupting quorum-sensing mechanisms. RIP was tested in the present study for its ability to inhibit S. aureus biofilm formation in a rat Dacron graft model. The activity of RIP was synergistic with those of antibiotics for the complete prevention of drug-resistant S. aureus infections.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Antibiotic Prophylaxis
  • Biofilms / drug effects
  • Biofilms / growth & development*
  • Cell Communication / drug effects
  • Colony Count, Microbial
  • Drug Synergism
  • Male
  • Microbial Sensitivity Tests
  • Oligopeptides / pharmacology*
  • Polyethylene Terephthalates
  • Prostheses and Implants / microbiology*
  • Rats
  • Rats, Wistar
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / growth & development*

Substances

  • Anti-Bacterial Agents
  • Oligopeptides
  • Polyethylene Terephthalates
  • RNAIII inhibiting peptide